Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses
Recruiting
N/A
Interventional Study
Schizophrenia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 60
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 200 (estimated)
- Sponsor
- Centre Hospitalier St Anne · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive impairment and social isolation. Treatments with antipsychotics have proven effective in improving their living conditions, but poor compliance results in relapses and rehosp…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Affiliated to a social security or other social protection scheme
* Diagnosed with schizophrenia according to the DSM-5 (code F20)
* Stable state without duration criteria
* Main treatment with risperidone or paliperidone, aripiprazole, olanzapine in oral or long-acting inject…
Contacts